How Targeted Radiotherapy Is Changing Cancer Care w/ John Babich, President, CSO, Ratio Therapeutics
Episode Description
For decades, cancer treatment has rested on three pillars: surgery, chemotherapy, and external beam radiation. A fourth is now taking shape, and it is drawing billions in investment from some of the largest pharmaceutical companies in the world.
John Babich, Founder, President, and Chief Scientific Officer of Ratio Therapeutics, joins host David E. Williams to explain how targeted radiotherapeutics pair a tumor-seeking molecule with a radioactive payload, delivering radiation to cancer cells while sparing healthy tissue. He also unpacks what Pluvicto’s success in prostate cancer signals for the future of radioligand therapy.
🎙️⚕️ABOUT JOHN BABICH
John W. Babich, a native of New York City, holds a BS in pharmaceutical sciences from St. John’s University and a PhD in radiopharmaceutical chemistry from The Institute of Cancer Research in London. He began his career at Brookhaven National Laboratory and later NASA, focusing on cardiovascular imaging. Babich co-founded Molecular Insight Pharmaceuticals in 1998, where he developed several radiopharmaceuticals, including a PSMA inhibitor for prostate cancer now in Phase 3 trials. In 2017, he founded Noria Therapeutics, which was sold to Bayer in 2021, leading to the creation of Ratio Therapeutics.
🎙️⚕️ABOUT HEALTH BIZ PODCAST
HealthBiz is a CareTalk podcast that delivers in-depth interviews on healthcare business, technology, and policy with entrepreneurs and CEOs. Host David E. Williams — president of the healthcare strategy consulting boutique Health Business Group — is also a board member, investor in private healthcare companies, and author of the Health Business Blog. Known for his strategic insights and sharp humor, David offers a refreshing break from the usual healthcare industry BS.
Need a Strategy Partner?
For over 20 years, Health Business Group has helped healthcare software companies, tech-enabled services businesses, life sciences companies, and payers make smarter strategic decisions. Led by podcast host David Williams, the firm advises clients on sharpening AI positioning, entering new segments, and building commercial strategies for value-based care. See examples of our work at healthbusinessgroup.com/
✨THIS VIDEO BROUGHT YOU BY:
PIM Health:
At PIM Health, we’re building real-time payment infrastructure where providers don’t wait weeks to get paid, patients don’t leave without knowing exactly what they owe, and employers stop flying blind on their own plan spend. AR burden, gone. Surprise bills, gone. Prior auth delays, gone. Denials and appeals, gone.
Learn what PIM Health is building here
Vector Sciences:
Dr. Dan Barouch and active angel investor and biotech lawyer Kris Brown are excited to join an upcoming CareTalk podcast discussion about the future of vaccines, biodefense preparedness, and why next-generation adenoviral and mucosal vaccine technologies may play an important role alongside mRNA approaches in addressing future global outbreaks. Looking forward to discussing how scalable, durable, and potentially transmission-blocking vaccine platforms could reshape pandemic response and global public health.
Hear more about Vector Sciences here
GET IN TOUCH
Follow CareTalk on LinkedIn
Become a CareTalk sponsor
Guest appearance requests
Visit us on the web
⚙️CareTalk: Healthcare. Unfiltered. is produced by Grippi Media Digital Marketing Consulting.
